Rosuvastatin more effective than atorvastatin in ACS

10:13 am Health Care

The lipid-modifying effects of rosuvastatin are stronger than atorvastatin in patients with acute coronary syndrome (ACS), according to new data from the LUNAR trial published in the American Journal of Cardiology in February this year. The LUNAR trial involved 825 adults with coronary artery disease who were hospitalized for ACS within 48 hours of first symptoms. They were randomly assigned to once-daily rosuvastatin 20 or 40 mg or atorvastatin 80 mg for 12 weeks.

Rosuvastatin 40 mg was significantly more effective at lowering LDL cholesterol compared to atorvastatin 80 mg (with decreases of 46.8% vs 42.7%; p=0.02). Efficacy was similar with rosuvastatin 20 mg and atorvastatin 80 mg.

Increases in HDL cholesterol were also significantly greater with rosuvastatin 40 mg (11.9%; p<0.001) and rosuvastatin 20 mg (9.7%; p<0.01) than with atorvastatin 80 mg (5.6%).

Still, the finding that rosuvastatin 20 mg was as effective as atorvastatin 80 mg in decreasing LDL cholesterol with a similar safety profile suggests that this dose of rosuvastatin might be considered an alternative to atorvastatin 80 mg in patients with ACS. [HeartWire]

Comments are closed.